UNSPSC 51151538: Cevimeline hydrochloride

This classification denotes a cholinergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P81Q6V85NP. European Medicines Agency schedules Cevimeline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01186MIG. Cevimeline hydrochloride generally arises in the molecular formula 2C10H17NOS.2CLH.H2O. The term 'cevimeline hydrochloride' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule cevimeline hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, CEVIMELINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cevimeline hydrochloride bears US NLM identifiers UMLS ID C0874063 and NCI Concept Code C1337. SMILES: C[C@H]1O[C@@]2(CN3CCC2CC3)CS1.C[C@H]1O[C@@]2(CN3CCC2CC3)CS1.O.CL.CL.

UNSPSC 51151538 Cevimeline hydrochloride is a Commodity code for a specific pharmaceutical product, but the recent state and local opportunities posted under this code reflect substantial scope mismatch. Seminole County, Florida's IFB60459723LAS solicits naloxone and drug deactivation systems — different pharmaceutical products entirely — while the Texas Health and Human Services Commission's RFI HHS0017013 addresses pharmacy benefit management and direct-to-manufacturer prescription programs at the systems level, not procurement of cevimeline hydrochloride or any named pharmaceutical line item. The code shows little relevant recent activity aligned with its nominal scope.

Geographic activity appears concentrated in Florida and Texas based on the two most recent postings, though neither opportunity actually targets cevimeline hydrochloride procurement. The Seminole County solicitation, posted June 30, 2026, with a response deadline of July 26, 2023 (the due date shown in the source), seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through IFB with quarterly deliveries to Sanford, Florida; vendors must include shipping costs and meet E-Verify and workers' compensation insurance requirements. The Texas HHS Commission's April 2026 RFI, with a response deadline of April 3, 2026, gathers vendor intelligence on direct-to-manufacturer pharmacy programs for state employees and self-insured plans but does not name specific pharmaceuticals or purchasing volumes. Business development professionals should verify whether cevimeline hydrochloride demand exists within state and local health systems, education, or corrections operations; the code's recent posting history does not yet support pursue decisions based on actual solicitation volume or frequency in this category.